Roth Capital analyst Jonathan Aschoff lowered the firm's price target on Cellectar Biosciences to $11 from $14 and keeps a Buy rating on the shares. Cellectar Biosciences reported positive 12-month Phase 2 data for iopofosine I 131 in Waldenstrom macroglobulinemia, demonstrating durable responses across patient groups and supporting the potential for an accelerated approval filing ahead of a planned Phase 3 initiation in Q4, the analyst tells investors in a research note.
